02:13:21 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-28 Halvårsrapport
2024-03-25 X-dag ordinarie utdelning FARON 0.00 EUR
2024-03-22 Årsstämma
2024-03-14 Bokslutskommuniké 2023
2023-08-29 Halvårsrapport
2023-03-27 X-dag ordinarie utdelning FARON 0.00 EUR
2023-03-24 Årsstämma
2023-03-03 Bokslutskommuniké 2022
2022-08-25 Halvårsrapport
2022-07-07 Extra Bolagsstämma 2022
2022-04-25 X-dag ordinarie utdelning FARON 0.00 EUR
2022-04-22 Årsstämma
2022-03-25 Bokslutskommuniké 2021
2021-08-26 Halvårsrapport
2021-04-26 X-dag ordinarie utdelning FARON 0.00 EUR
2021-04-23 Årsstämma
2021-03-25 Bokslutskommuniké 2020
2020-05-14 X-dag ordinarie utdelning FARON 0.00 EUR
2020-05-13 Årsstämma
2020-03-20 Bokslutskommuniké 2019

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriBioteknik
Faron Pharmaceuticals är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling av terapeutiska lösningar som används för behandling av immuna sjukdomar och diverse organskador. Störst verksamhet återfinns inom Nordamerika samt Europa, med sjukhus och forskningsinstitut som dominerande kundbas. Utöver huvudverksamheten erbjuds diverse mervärdestjänster. Huvudkontoret ligger i Turku.
2022-12-23 08:00:00

Faron Pharmaceuticals Oy
("Faron" or "Company")

Faron's Financial Calendar for 2023

Company announcement, December 23, 2022 at 9.00 am (EET) / 07:00 AM (GMT) / 02:00 AM (EDT)

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on tackling difficult-to-treat cancers and inflammation via precision immunotherapy, today announces the following dates for the Company's financial reporting in 2023:

March 2Financial statement release for the full year 2022 and Annual Report 2022 including financial statements for the full year

August 29 Half-year financial report for the period January 1 to June 30, 2023

The annual general meeting is planned to be held on March 24, 2023. A separate stock exchange notice will be issued by Faron's board of directors to convene the meeting.

For more information please contact:

Investor Contact

Faron Pharmaceuticals

Julia Balanova

VP, Investor Relations

julia.balanova@faron.com

investor.relations@faron.com

Phone: +1 (917) 306-6096
Faron Pharmaceuticals

Toni Hänninen

CFO

toni.hanninen@faron.com (Yrjo.wichmann@faron.com)

Phone: +41 79 387 2643

Media Contact

Faron Pharmaceuticals

Jennifer Smith-Parker

Head of Communications

Jennifer.Smith-Parker@faron.com

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

Consilium Strategic Communications

David Daley, Lindsey Neville, Namrata Taak

faron@consilium-comms.com

Phone: +44 (0)20 3709 5700

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with solid tumors and hematologic malignancies, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated by the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma.  Faron is based in Turku, Finland. Further information is available at www.faron.com.